Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors

The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors

DLTs = dose-limiting toxicities

MTD = Maximum tolerated dose

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is considered appropriate
• Subjects with non-small cell lung cancer and triple-negative breast cancer are preferred
• Biopsy accessible tumor (may use archived tumor samples under certain circumstances)
• Life expectancy of at least 3 months
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
• Measurable disease

Exclusion Criteria:

• Uncontrolled brain metastases
• Infection
• Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory bowel disease)
• Uncontrolled or significant cardiovascular disease
• Subjects taking medications known to increase risk of Torsades de Pointes